Join Our List
	Current Profile Profiles Resources Contact Us Subscribe  Home					Enter Email Address
Corporate Information Symbol: ARYC Exchange: OTCBB Shares I/O: 3.0 million 52 Week Range: $0.01 - $5.00   Contact Information Investor Relations, Market Pulse Toll Free: 800.290.8935 Email: info@market-pulse.com Web Site: www.arrayit.com Latest News: ARYC News Recent Developments: February 24, 2010 - Arrayit Corporation President Dr. Mark Schena to Appear Live on the Television Program the Big Biz Show Get the Full Story February 18, 2010 - Arrayit Corporation Has Discovered a Pathway to True Health Care Reform With Pre-symptomatic Diagnostics Get the Full Story February 4, 2010 - Arrayit Wins Landmark DNA Testing Patent in Israel Get the Full Story January 25, 2010 - Arrayit Corporation's Proteomic Biomarkers Clear the Way for Pre-Symptomatic Detection of Ovarian Cancer and Other Major Diseases Get the Full Story January 19, 2010 - Arrayit Corporation Selected by Silicom Ventures to Present at the 2010 Personalized Medicine World Conference in Silicon Valley Get the Full Story January 7, 2010 - Major News Media Missed the Mark -- There Is a New Pre-Symptomatic Screening Test for Ovarian Cancer Coming From Arrayit Corporation, and It Will Be Available Soon Get the Full Story December 22, 2009 - Arrayit Corporation Announces Manufacturing Breakthrough Get the Full Story December 17, 2009 - Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 Get the Full Story December 10, 2009 - Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation Get the Full Story December 9, 2009 - Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics Get the Full Story November 30, 2009 - Arrayit Diagnostics Names Elite Financial Communications Group as Investor Relations/Public Relations Counsel Get the Full Story November 18, 2009 - Arrayit Technology Purchased by Johns Hopkins University to Study Rheumatoid Arthritis Get the Full Story November 12, 2009 - Arrayit Diagnostics Focused on Early Stage Disease Detection Get the Full Story November 5, 2009 - Arrayit Corporation to Diagnose Early Stage Cancers and Monitor Effectiveness of Treatments Get the Full Story November 2, 2009 - Arrayit Corporation Blood Tests Diagnose Early Stage Cancers and Communicable Diseases Get the Full Story October 28, 2009 - Arrayit Announces NanoPrint Sale to Leukemia Center in Poland Get the Full Story October 22, 2009 - Arrayit and the USDA Join Forces to Protect America's Crop Plants Get the Full Story October 15, 2009 - Will Arrayit Technology Identify Life on Mars? Get the Full Story October 7, 2009 - Arrayit Corporation CEO Reports to Shareholders Get the Full Story October 5, 2009 - Arrayit Deploys Next-Generation Proteomics Platform Get the Full Story September 28, 2009 - Arrayit Wins Contract With Austrian Institute of Technology for Detection of Highly Dangerous Pathogens Get the Full Story September 21, 2009 - Arrayit Wins Equipment Contract From Sandia National Laboratories Get the Full Story September 16, 2009 - Arrayit Wins Manufacturing Contract From the Centers for Disease Control Get the Full Story September 10, 2009 - Arrayit Offers Million Dollar Biomarker Discovery Service Get the Full Story September 2, 2009 - Arrayit Lands Patent for Population Scale Diagnostics in World's Most Populous Country Get the Full Story August 27, 2009 - Arrayit Technology Speeds Allergy Testing Get the Full Story August 18, 2009 - Arrayit Corp. Financials Get the Full Story August 12, 2009 - Arrayit Corporation Opens International Marketing Headquarters in Houston Get the Full Story July 23, 2009 - Arrayit Corporation Announces Worldwide Product Sales Up Nearly 50% Get the Full Story July 16, 2009 - Arrayit Corporation and Parkinson's Institute Implement New Screening Techniques for Identification of Molecular Biomarkers Get the Full Story June 24, 2009 - Mark Schena, PhD, Positions Arrayit Corporation to Enter Molecular Diagnostics Using VIP Technology Get the Full Story June 18, 2009 - Arrayit Corporation Addresses Flu Pandemic Get the Full Story April 30, 2009 - Arrayit to Mass Produce Rapid H1N1 Swine Flu Test Chip Get the Full Story April 30 , 2009 - Arrayit to Mass Produce Rapid H1N1 Swine Flu Test Chip Get the Full Story April 27, 2009 - Grass-Roots-Research (Grass-Roots-Distribution.com) Issues Positive Research Report on Arrayit Corporation Get the Full Story April 21, 2009 - Arrayit Speeds Analysis of the Human Genome Get the Full Story       The Company Arrayit Corporation (OTCBB: ARYC) develops, manufactures and markets life science technologies and integrated systems for the analysis of genetic variation, biological function, and diagnostics. Arrayit offers a product line of approximately 650 tools to 2,500 laboratories worldwide. The company's products include microarrayers, microarray scanners, DNA and protein microarrays, microarray printing, microarray substrates and slides, microarray instruments, amplification and labeling, purification kits, microarray hardware, buffers and solutions, microarray cleanrooms, books and software, CGH microarrays, and microarray platforms. Arrayit's worldwide business position leverages the company's widely used patented microarray manufacturing platform and revolutionary Variation Identification Platform (VIP™) genotyping technology. Nearly every major research center in the world uses Arrayit products including research laboratories, pharmaceutical companies, universities, biotechnology companies, hospitals, government agencies, and nonprofit research organizations. The company is also involved in the import, export, and distribution of industrial and food grade chemicals for plastics, fertilizers, and green energy applications. On April 9, 2009, the company formed a new research collaboration with the Parkinson's Institute to discover biomarkers for Parkinson's disease. The collaboration is expected to provide diagnosis of 3,000 patients per year. Business alliances for the early detection of ovarian cancer and with BioSystems International to identify predictors and biomarkers for Parkinson’s disease and Alzheimer’s disease, will further boost revenue in the mid-to-long term time frame. Arrayit recently announced that its microarray-based diagnostic test, VIP™, is ready for manufacture and distribution. A breakthrough screening test using VIP™ will allow clinicians and researchers to test and detect the H1N1 swine flu virus in population wide studies. The VIP screening test is the first of its kind developed for multiple numbers of test subjects, with diagnosis available to patients within hours of testing. Up to 80,000 patients can be screened at a time, making it possible for entire communities and entire countries to quickly identify those infected with the new H1N1 virus. The Technology Genes, mRNAs and proteins work in concert in the human body to determine our health. Genes are made of DNA and the DNA blueprint in our cells is inherited from our parents. Each person has variations in their DNA blueprint. Most DNA variations in the DNA code have little or no impact on a person’s health, but certain variations can cause serious diseases such as sickle cell anemia, cystic fibrosis, Parkinson’s Disease, hereditary hearing loss, ovarian cancer and other clinical conditions. Identifying variations in the DNA blueprint is performed using a process known as genotyping. Genotyping allows scientists and doctors to detect disease-causing variations in the DNA code. The challenge in genotyping is to affordably test the DNA from hundreds, thousands, and even millions of patients quickly and easily. Genotyping information is used to make medical decisions, so the genotyping process must also be highly accurate and capable of analyzing every gene in the human body. Arrayit has developed and patented the world’s finest platform for analyzing DNA, mRNA and protein molecules found in the human body. The Arrayit platform uses a revolutionary device known as a microarray. Arrayit microarrays are glass substrates that contain DNA spots representing all 25,000 genes in the human genome (blueprint). An Arrayit microarray functions like a biological computer chip, rapidly computing information about each gene in the human body. Patient DNA, mRNA or protein molecules are obtained from a tissue sample such as small amount of human blood. The samples are labeled with fluorescent tags and mixed with a microarray to allow binding of each spot on the microarray with fluorescent molecules in the patient sample. Molecular interactions between the microarray spots and patient molecules cause each spot on the microarray to glow with an intensity consistent with the amount of DNA, mRNA or protein present in the sample. High-speed scanning of the fluorescent microarray provides quantitative data for every gene in the human body in about 5 minutes. Arrayit’s VIP™ microarrays enable the analysis of the DNA from 100,000 patients in one experiment. The industry norm is one experiment per patient. The technology provides a distinct competitive advantage. Arrayit offers a full suite of microarray services including custom DNA and protein microarray manufacturing, consulting, training videos, government purchasing, a microarray electronic library, product catalogs, and more. The Products Arrayit has been a microarray technology market leader for more than a decade. Arrayit offers a product line of approximately 650 tools to 2,500 laboratories worldwide. The current portfolio of products and services serve the sequencing, genotyping, gene expression and protein analysis markets. The company expects to enter the lucrative market for molecular diagnostics. The company has a comprehensive set of microarray services including custom DNA and protein microarray manufacturing, consulting, training videos, government purchasing, a microarray electronic library, product catalogues, and more. Current Product Portfolio: Microarrays Microarray Scanners DNA Microarrays Protein Microarrays Microarray Printing Microarray Substrates & Slides Microarray Instruments Amplification & Labeling Purification Kits Microarray Tools Buffers & Solutions Microarray Cleanrooms Books & Software CGH microarrays Microarray Platforms The Market The 2009 swine flu outbreak has raised concerns at the CDC and the World Health Organization (WHO). The CDC and WHO believe that the current outbreak poses a pandemic risk because the H1N1 flu virus contains genetic elements from both the swine and human influenza viruses, allowing direct human-to-human transmission without the need for agricultural contact. The dangerous 2009 strain has little immunity in the human population, resistance to several common anti-viral drugs, and has caused serious illness and death. A Department of Health and Human Services spokesperson said, "In the event of an emerging pandemic, the CDC-IRR (Influenza Reagent Resource) will serve as a source of reagents for qualified laboratories to provide additional support. During a pandemic, laboratories will play a critical role in detecting and confirming initial cases, characterizing viruses, monitoring the progression of the pandemic, and selecting vaccine strains. Scientists around the world are concerned that the influenza virus could one day mutate and acquire the properties needed to quickly spread between people, resulting in a pandemic." Arrayit's unique microarray platform allows the design, manufacture and distribution of H1N1 chip technology quickly and inexpensively, owing to the Company's unique and patented contact printing technology, versatile system architecture, and broad customer base. "Our team is able to leverage the most sophisticated and accurate gene testing available on the market today to rapidly and affordably bring this H1N1 flu chip test to market," said Rene Schena, Chief Executive Officer of Arrayit Corporation. The company’s products and services are used in the life sciences, pharmaceutical, and diagnostics markets, which are estimated at $690 billion in annual revenue. The company anticipates new business of more than $3 million with projected revenues of $7.6 million in 2009 and $46.7 million in 2011. The recent agreement with The Parkinson's Institute illustrates the company's strategic growth plan. The deal is expected to produce approximately 3000 patients per year. The collaboration for hearing loss tests will also be a major contributor to revenue growth in the short term. It is estimated that the equipment division will rapidly grow to a $15.4 million dollar business over a 5 year projected period. Management Team Rene' A. Schena - Chief Executive Officer Mark Schena Ph.D. - President Todd J. Martinsky - Executive Vice President Paul K. Haje - Director of Public Relations Bill Sklar - Chief Financial Officer Khrystyne Haje - Company Spokesperson The Future Arrayit is an exciting and innovative public company that strives to increase shareholder equity by inventing, developing, manufacturing and supplying sophisticated life sciences products and services to an extensive customer base spanning 50 countries. Arrayit is a leader in the field of molecular diagnostics with patented technology that allows the screening and monitoring of up to 80,000 patient samples on a single microscope slide, rather than testing one patient per slide as is currently practiced. Their corporate philosophy is embodied by a highly skilled, multidisciplinary team of investors, business professionals, scientists, engineers and executive and support staff who place shareholder value, product quality, customer service and price competitiveness as their highest priorities. Arrayit empowers decisive strategic advantage and large return on investment for their customers in the research, pharmaceutical, diagnostic, and health care markets. Arrayit presents a potentially substantial growth opportunity. MP has been compensated, in connection with its profile of Arrayit Corporation, one hundred thousand shares of Arrayit Corporation's common stock by a third party shareholder. Additionally, MP bought for its own account in the open market, forty thousand shares of Arrayit Corporation's shares for a total purchase price of twenty three thousand eight hundred twenty dollars. To date, MP has sold seventy eight thousand seven hundred shares of stock in Arrayit Corporation for proceeds totaling seventy seven thousand seventy nine dollars. For additional information relating to MP, please review our disclosure page through our disclaimer link.

Current Profile | Profiles | Resources | Subscribe | Contact Us | Disclaimer
Market Pulse Navigator All Rights Reserved.
© Copyright 2010